Discussion stirs around OraSure Technologies, Inc. (NASDAQ:OSUR) this week; here is what analysts are saying.

June 13, 2018 - By Darrin Black

Investors sentiment increased to 1.08 in Q1 2018. Its up 0.25, from 0.83 in 2017Q4. It increased, as 15 investors sold OraSure Technologies, Inc. shares while 57 reduced holdings. 29 funds opened positions while 49 raised stakes. 54.02 million shares or 0.43% more from 53.79 million shares in 2017Q4 were reported.
Moreover, State Bank Of America Corporation De has 0% invested in OraSure Technologies, Inc. (NASDAQ:OSUR) for 127,141 shares. Manufacturers Life The reported 41,894 shares. Panagora Asset Inc stated it has 63,639 shares or 0% of all its holdings. California State Teachers Retirement System owns 86,196 shares or 0% of their US portfolio. Blackrock has invested 0.01% in OraSure Technologies, Inc. (NASDAQ:OSUR). Vantage Inv Advsrs Ltd owns 30 shares. Schwab Charles Inv Management has 288,871 shares. Arizona State Retirement Systems reported 96,140 shares stake. Mckinley Capital Management Ltd Liability Co Delaware accumulated 8,673 shares. Victory Capital Management has invested 0% in OraSure Technologies, Inc. (NASDAQ:OSUR). First Washington holds 244,520 shares. New York-based Bank & Trust Of Mellon Corp has invested 0% in OraSure Technologies, Inc. (NASDAQ:OSUR). Morgan Stanley holds 0% or 602,201 shares. Great West Life Assurance Can, Manitoba – Canada-based fund reported 79,373 shares. Domini Impact Investments Ltd Company invested in 9.86% or 29,806 shares.

Since February 15, 2018, it had 0 insider buys, and 2 sales for $778,707 activity. TANG STEPHEN S PHD also sold $419,247 worth of OraSure Technologies, Inc. (NASDAQ:OSUR) shares.

OraSure Technologies, Inc. (NASDAQ:OSUR) Ratings Coverage

Among 3 analysts covering Orasure Technologies (NASDAQ:OSUR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Orasure Technologies had 3 analyst reports since December 15, 2017 according to SRatingsIntel. As per Tuesday, February 13, the company rating was maintained by Jefferies. The firm has “Buy” rating by Canaccord Genuity given on Friday, February 2. Below is a list of OraSure Technologies, Inc. (NASDAQ:OSUR) latest ratings and price target changes.

13/02/2018 Broker: Jefferies Rating: Hold New Target: $17.5 Maintain
02/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $24.0 Maintain
15/12/2017 Broker: Raymond James Rating: Buy

The stock increased 0.92% or $0.16 during the last trading session, reaching $17.5. About 308,590 shares traded. OraSure Technologies, Inc. (NASDAQ:OSUR) has risen 9.53% since June 13, 2017 and is uptrending. It has underperformed by 3.04% the S&P500.

OraSure Technologies, Inc., together with its subsidiaries, develops, makes, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company has market cap of $1.07 billion. It operates in two divisions, OSUR and DNAG. It has a 34.31 P/E ratio. The firm also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

More news for OraSure Technologies, Inc. (NASDAQ:OSUR) were recently published by: Equitiesfocus.com, which released: “Critical Comparison: Novocure (NVCR) vs. OraSure Technologies (OSUR)” on June 13, 2018. Globenewswire.com‘s article titled: “OraSure Technologies to Present at Jefferies Global Healthcare Conference” and published on May 16, 2018 is yet another important article.

OraSure Technologies, Inc. (NASDAQ:OSUR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: